|
|
|||
|
|||
|
|
|||
|
perfume allergies |
|||
|
|
|||
|
|||
 
|
|||
|
|
|||
|
perfume allergies DESCRIPTION Zafirlukast is a synthetic, selective peptide leukotriene receptor antagonist(LTRA), with the chemical name 4-(5-cyclopentyloxy-carbonylamino-1-methyl-indol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide perfume allergies. The molecular weight of zafirlukast is 575.7 and the structural formula is:
Zafirlukast, a fine white to pale yellow amorphous powder, is practically insolublein water perfume allergies. It is slightly soluble in methanol and freely soluble in tetrahydrofuran,dimethylsulfoxide, and acetone perfume allergies. ACCOLATE is supplied as 10 and 20 mg tablets for oral administration perfume allergies. Inactive Ingredients: Film-coated tablets containing croscarmellose sodium,lactose, magnesium stearate, microcrystalline cellulose, povidone, hypromellose,and titanium dioxide perfume allergies.
In vitro studies demonstrated that zafirlukast antagonized the contractileactivity of three leukotrienes (LTC 4 , LTD 4 and LTE 4 ) in conducting airwaysmooth muscle from laboratory animals and humans perfume allergies. Zafirlukast prevented intradermalLTD 4 -induced increases in cutaneous vascular permeability and inhibited inhaledLTD 4 -induced influx of eosinophils into animal lungs perfume allergies. Inhalational challengestudies in sensitized sheep showed that zafirlukast suppressed the airway responsesto antigen; this included both the early- and late-phase response and the nonspecifichyperresponsiveness perfume allergies. In humans, zafirlukast inhibited bronchoconstriction caused by several kindsof inhalational challenges perfume allergies. Pretreatment with single oral doses of zafirlukastinhibited the bronchoconstriction caused by sulfur dioxide and cold air in patientswith asthma perfume allergies. Pretreatment with single doses of zafirlukast attenuated the early-and late-phase reaction caused by inhalation of various antigens such as grass,cat dander, ragweed, and mixed antigens in patients with asthma perfume allergies. Zafirlukastalso attenuated the increase in bronchial hyperresponsiveness to inhaled histaminethat followed inhaled allergen challenge perfume allergies. Clinical Pharmacokinetics and Bioavailability: Distribution Metabolism Excretion In the pivotal bioequivalence study, the mean terminal half-life of zafirlukastis approximately 10 hours in both normal adult subjects and patients with asthma perfume allergies. In other studies, the mean plasma half-life of zafirlukast ranged from approximately8 to 16 hours in both normal subjects and patients with asthma perfume allergies. The pharmacokineticsof zafirlukast are approximately linear over the range from 5 mg to 80 mg perfume allergies. Steady-stateplasma concentrations of zafirlukast are proportional to the dose and predictablefrom single-dose pharmacokinetic data perfume allergies. Accumulation of zafirlukast in the plasmafollowing twice-daily dosing is approximately 45% perfume allergies. The pharmacokinetic parameters of zafirlukast 20 mg administered as a singledose to 36 male volunteers are shown with the table below perfume allergies. Mean (% Coefficient of Variation) pharmacokinetic
Race: No differences in the pharmacokinetics of zafirlukast due to race havebeen observed perfume allergies. Elderly: The apparent oral clearance of zafirlukast decreases with age perfume allergies. Inpatients above 65 years of age, there is an approximately 2-3 fold greater Cmax and AUC compared to young adult patients perfume allergies. Children: Following administration of a single 20 mg dose of zafirlukast to20 boys and girls between 7 and 11 years of age, and in a second study, to 29boys and girls between 5 and 6 years of age, the following pharmacokinetic parameterswere obtained: Parameter Children age
Zafirlukast disposition was unchanged after multiple dosing (20 mg twice daily)in children and the degree of accumulation in plasma was similar to that observedin adults perfume allergies. Hepatic Insufficiency: In a study of patients with hepatic impairment (biopsy-provencirrhosis), there was a reduced clearance of zafirlukast resulting in a 50-60%greater C max and AUC compared to normal subjects perfume allergies. Renal Insufficiency: Based on a cross-study comparison, there are no apparentdifferences in the pharmacokinetics of zafirlukast between renally-impairedpatients and normal subjects perfume allergies. Drug-Drug Interactions
|
|||
 
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
| pperfume allergies peerfume allergies perrfume allergies perffume allergies perfuume allergies perfumme allergies perfumee allergies perfume allergies perfume aallergies perfume alllergies perfume alllergies perfume alleergies perfume allerrgies perfume allerggies perfume allergiies perfume allergiees perfume allergiess erfume allergies prfume allergies pefume allergies perume allergies perfme allergies perfue allergies perfum allergies perfumeallergies perfume llergies perfume alergies perfume alergies perfume allrgies perfume allegies perfume alleries perfume allerges perfume allergis perfume allergie p erfume allergies pe rfume allergies per fume allergies perf ume allergies perfu me allergies perfum e allergies perfume allergies perfume allergies perfume a llergies perfume al lergies perfume all ergies perfume alle rgies perfume aller gies perfume allerg ies perfume allergi es perfume allergie s perfume allergies eprfume allergies prefume allergies pefrume allergies perufme allergies perfmue allergies perfuem allergies perfum eallergies perfumea llergies perfume lalergies perfume allergies perfume alelrgies perfume allregies perfume allegries perfume alleriges perfume allergeis perfume allergise aperfume allergies theperfume allergies perfume allergies | |||
|
|
|||
|
|
|||
|
|
|||
|
Copyright 2005 D-S LTD. |
